St. Louis, MO – 26 May 2015– BacterioScan Inc. announced that American Society of Microbiology has accepted four abstracts for publication during the society’s largest gathering, the ASM General Meeting (New Orleans, May 2015).
The abstracts summarize BacterioScan’s most recent research successes using the BacterioScan (model 216R) as a rapid, phenotypic diagnostic for antibiotic resistance testing and rapid Urinary Tract Infection (UTI) detection. “Having our research accepted for publication by ASM is tremendous recognition and validation for us” said BacterioScan’s President and CEO, Dana Marshall.
The company’s premier product (Model 216Dx) provides rapid detection of UTI, the most common bacterial infection in humans. The BacterioScan product is targeted toward helping hospitals and clinical microbiology labs rapidly process the approximately 100 million UTI specimens collected each year worldwide. With rapid detection, the BacterioScan system reduces the processing time from several days to less than two hours for the vast majority of specimens. Additionally, UTI accounts for about 40% of all hospital-acquired infections, and the BacterioScan technology is aimed to help hospitals reduce and manage this serious and costly problem.
“The BacterioScan (Model 216Dx) instrument can rapidly detect bacterial infections at detection thresholds well below patient symptomatic levels, providing hospitals with the ability to treat infections before they reach a point which would add complexity to other care paths, said Dana Marshall, BacterioScan’s President and CEO. “Additionally, the rapid diagnosis of UTI, and determination of antibiotic susceptibility can improve the quality of antibiotic therapy selected, reducing the excess or inappropriate use of antibiotics, and reducing opportunities for emergence of resistance.”
Today the BacterioScan instruments are at work in several world-class research hospitals and universities examining their capability to rapidly detect antibiotic resistance and susceptibility in various types of bacterial infections. Initial work, including recent publications from the US Centers for Disease Control (CDC), St. Jude’s Children’s Research Hospital and others, has indicated that the technology can reduce the time for selection of effective antibiotic therapy from 30+ hours to less than 3 hours, offering a potential breakthrough in addressing the worldwide urgent challenge of antibiotic resistance.
About BacterioScan Inc.
BacterioScan Inc. is an in-vitro diagnostics (IVD) company focused on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. BacterioScan’s instruments can rapidly detect infection, determine if it is resistant to a range of antibiotics, and provide clinicians with patient-specific guidance on the most rapid and cost-effective treatment plan. BacterioScan’s first medical device product is a compact, simple, and low-cost system for rapid detection of Urinary Tract Infection (UTI) for use in clinical microbiology labs. BacterioScan is a privately held global corporation, with headquarters in St Louis, Missouri.
Help employers find you! Check out all the jobs and post your resume.
The abstracts summarize BacterioScan’s most recent research successes using the BacterioScan (model 216R) as a rapid, phenotypic diagnostic for antibiotic resistance testing and rapid Urinary Tract Infection (UTI) detection. “Having our research accepted for publication by ASM is tremendous recognition and validation for us” said BacterioScan’s President and CEO, Dana Marshall.
The company’s premier product (Model 216Dx) provides rapid detection of UTI, the most common bacterial infection in humans. The BacterioScan product is targeted toward helping hospitals and clinical microbiology labs rapidly process the approximately 100 million UTI specimens collected each year worldwide. With rapid detection, the BacterioScan system reduces the processing time from several days to less than two hours for the vast majority of specimens. Additionally, UTI accounts for about 40% of all hospital-acquired infections, and the BacterioScan technology is aimed to help hospitals reduce and manage this serious and costly problem.
“The BacterioScan (Model 216Dx) instrument can rapidly detect bacterial infections at detection thresholds well below patient symptomatic levels, providing hospitals with the ability to treat infections before they reach a point which would add complexity to other care paths, said Dana Marshall, BacterioScan’s President and CEO. “Additionally, the rapid diagnosis of UTI, and determination of antibiotic susceptibility can improve the quality of antibiotic therapy selected, reducing the excess or inappropriate use of antibiotics, and reducing opportunities for emergence of resistance.”
Today the BacterioScan instruments are at work in several world-class research hospitals and universities examining their capability to rapidly detect antibiotic resistance and susceptibility in various types of bacterial infections. Initial work, including recent publications from the US Centers for Disease Control (CDC), St. Jude’s Children’s Research Hospital and others, has indicated that the technology can reduce the time for selection of effective antibiotic therapy from 30+ hours to less than 3 hours, offering a potential breakthrough in addressing the worldwide urgent challenge of antibiotic resistance.
About BacterioScan Inc.
BacterioScan Inc. is an in-vitro diagnostics (IVD) company focused on the rapid detection and real-time quantification of bacteria in fluid using optical measurements. BacterioScan’s instruments can rapidly detect infection, determine if it is resistant to a range of antibiotics, and provide clinicians with patient-specific guidance on the most rapid and cost-effective treatment plan. BacterioScan’s first medical device product is a compact, simple, and low-cost system for rapid detection of Urinary Tract Infection (UTI) for use in clinical microbiology labs. BacterioScan is a privately held global corporation, with headquarters in St Louis, Missouri.
Help employers find you! Check out all the jobs and post your resume.
